MSL1

Summary

MSL1 (MSL complex subunit 1, HGNC:27905) is a protein-coding gene on chromosome 17q21.1, encoding Male-specific lethal 1 homolog (Q68DK7). Non-catalytic component of the MSL histone acetyltransferase complex, a multiprotein complex that mediates the majority of histone H4 acetylation at ‘Lys-16’ (H4K16ac), an epigenetic mark that prevents chromatin compaction. It is a selective cancer dependency (DepMap: 26.5% of cell lines).

Enables protein-macromolecule adaptor activity. Involved in positive regulation of DNA-templated transcription. Located in nucleoplasm. Part of MSL complex.

Source: NCBI Gene 339287 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 46 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 26.5% of screened cell lines
• MANE Select transcript: NM_001365919

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27905
Approved symbol	MSL1
Name	MSL complex subunit 1
Location	17q21.1
Locus type	gene with protein product
Status	Approved
Aliases	hMSL1, MSL-1, DKFZp686P24239
Ensembl gene	ENSG00000188895
Ensembl biotype	protein_coding
OMIM	614801
Entrez	339287

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 6 protein_coding, 5 retained_intron, 1 nonsense_mediated_decay

ENST00000339569, ENST00000398532, ENST00000577454, ENST00000578648, ENST00000578826, ENST00000579565, ENST00000580086, ENST00000581246, ENST00000582884, ENST00000582920, ENST00000583127, ENST00000947390

RefSeq mRNA: 4 — MANE Select: NM_001365919 NM_001012241, NM_001365919, NM_001365920, NM_001365921

CCDS: CCDS45670, CCDS92297, CCDS92298, CCDS92299

Canonical transcript exons

ENST00000398532 — 9 exons

Exon	Start	End
ENSE00001726739	40129245	40129627
ENSE00002694593	40121971	40123380
ENSE00002723822	40134279	40136917
ENSE00003508999	40132034	40132098
ENSE00003550501	40133827	40133899
ENSE00003554521	40133534	40133658
ENSE00003572267	40131537	40131584
ENSE00003630912	40126183	40126406
ENSE00003674340	40133042	40133109

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 98.89.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.3887 / max 346.9585, expressed in 1814 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160682	13.2326	1769
160680	11.3829	1787
160681	0.8610	470
160683	0.5683	250
160679	0.5536	311
160678	0.3923	225
160677	0.2441	103
160684	0.1539	51

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.89	gold quality
ganglionic eminence	UBERON:0004023	98.67	gold quality
cortical plate	UBERON:0005343	98.63	gold quality
endocervix	UBERON:0000458	98.08	gold quality
mucosa of stomach	UBERON:0001199	97.90	gold quality
body of uterus	UBERON:0009853	97.89	gold quality
right lung	UBERON:0002167	97.81	gold quality
right uterine tube	UBERON:0001302	97.71	gold quality
blood	UBERON:0000178	97.67	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.59	gold quality
cerebellar hemisphere	UBERON:0002245	97.57	gold quality
left uterine tube	UBERON:0001303	97.53	gold quality
cerebellar cortex	UBERON:0002129	97.50	gold quality
secondary oocyte	CL:0000655	97.45	gold quality
tibial nerve	UBERON:0001323	97.38	gold quality
left lobe of thyroid gland	UBERON:0001120	97.35	gold quality
right lobe of thyroid gland	UBERON:0001119	97.33	gold quality
descending thoracic aorta	UBERON:0002345	97.33	gold quality
ectocervix	UBERON:0012249	97.29	gold quality
right ovary	UBERON:0002118	97.24	gold quality
left ovary	UBERON:0002119	97.14	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.13	gold quality
pituitary gland	UBERON:0000007	97.08	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.07	gold quality
spleen	UBERON:0002106	97.04	gold quality
lower esophagus muscularis layer	UBERON:0035833	97.01	gold quality
right testis	UBERON:0004534	97.00	gold quality
lower esophagus	UBERON:0013473	97.00	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.95	gold quality
cerebellum	UBERON:0002037	96.94	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.57
E-MTAB-7249	no	829.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

128 targeting MSL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 26.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• A multisubunit human histone acetylase complex that contains homologs of the Drosophila MSL proteins MOF, MSL1 (hampin A), MSL2, and MSL3 was described. This complex is responsible for histone H4 lysine-16 acetylation of all cellular chromosomes. (PMID:16227571)
• MSL1 plays an important role in mediating irradiation-induced DNA repair through formation of HAT complexes and interaction with 53BP1. P8 acts as a negative regulator of this process by interacting with MSL1 and preventing its role on HAT activity. (PMID:19650074)
• The MSL1 bound to Nupr1, with a moderate affinity (2.8 microM) in an entropically-driven process. MSL1 did not bind to non-damaged DNA, but it bound to chemically-damaged-DNA with a moderate affinity (1.2 microM) also in an entropically-driven process. (PMID:24205110)
• Studies identi fi ed a novel signal of nuclear localization (NLS) in all MSL1 protein isoforms and found that the combination of both NLS allows for its intra-nuclear focal accumulation and nuclear transport of TTC4 while all MSL1 isoforms affect H4K16Ac. (PMID:24913909)
• Shift in MSL1 alternative polyadenylation in response to DNA damage protects cancer cells from chemotherapeutic agent-induced apoptosis. (PMID:34644577)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	msl1a	ENSDARG00000074734
danio_rerio	msl1b	ENSDARG00000090223
mus_musculus	Msl1	ENSMUSG00000052915
rattus_norvegicus	Msl1	ENSRNOG00000009643
drosophila_melanogaster	msl-1	FBGN0005617
drosophila_melanogaster	CG12316	FBGN0036483

Protein

Protein identifiers

Male-specific lethal 1 homolog — Q68DK7 (reviewed: Q68DK7)

Alternative names: Male-specific lethal 1-like 1, Male-specific lethal-1 homolog 1

All UniProt accessions (5): J3KRQ4, Q68DK7, J3KSZ8, J3KTC2, J3QQY0

UniProt curated annotations — full annotation on UniProt →

Function. Non-catalytic component of the MSL histone acetyltransferase complex, a multiprotein complex that mediates the majority of histone H4 acetylation at ‘Lys-16’ (H4K16ac), an epigenetic mark that prevents chromatin compaction. The MSL complex is required for chromosome stability and genome integrity by maintaining homeostatic levels of H4K16ac. The MSL complex is also involved in gene dosage by promoting up-regulation of genes expressed by the X chromosome. X up-regulation is required to compensate for autosomal biallelic expression. The MSL complex also participates in gene dosage compensation by promoting expression of Tsix non-coding RNA. Within the MSL complex, acts as a scaffold to tether MSL3 and KAT8 together for enzymatic activity regulation. Greatly enhances MSL2 E3 ubiquitin ligase activity, promoting monoubiquitination of histone H2B at ‘Lys-34’ (H2BK34Ub). This modification in turn stimulates histone H3 methylation at ‘Lys-4’ (H3K4me) and ‘Lys-79’ (H3K79me) and leads to gene activation, including that of HOXA9 and MEIS1.

Subunit / interactions. Component of a multisubunit histone acetyltransferase complex (MSL) at least composed of the KAT8/MOF/MYST1, MSL1/hampin, MSL2 and MSL3. Forms a MSL heterotetrameric core with MSL2. Interacts (via PEHE domain) with KAT8 (via HAT domain) and MSL3 (via MRG domain); both interactions are direct. Directly interacts with NUPR1. Interacts with TP53BP1; this interaction may be required for MSL1 DNA repair activity, but not for histone acetyltransferase activity. Interacts with TTC4, ECM2 and PIHD1.

Subcellular location. Nucleus. Nucleoplasm. Nucleus speckle.

Post-translational modifications. Sumoylated with SUMO1.

Domain organisation. The coiled coil is formed by helices from two subunits in the MSL1 homodimer.

Induction. Up-regulated by gamma-irradiation.

Similarity. Belongs to the msl-1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q68DK7-1	1	yes
Q68DK7-2	2
Q68DK7-3	3

RefSeq proteins (4): NP_001012241, NP_001352848, NP_001352849, NP_001352850 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026711	Msl-1	Family
IPR029332	PEHE_dom	Domain
IPR031840	MSL1_dimer	Domain

Pfam: PF15275, PF16801

UniProt features (34 total): compositionally biased region 7, modified residue 7, region of interest 6, cross-link 3, short sequence motif 2, splice variant 2, helix 2, chain 1, domain 1, sequence conflict 1, strand 1, coiled-coil region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
4DNC	X-RAY DIFFRACTION	2.05
4B7Y	X-RAY DIFFRACTION	3.25
4B86	X-RAY DIFFRACTION	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q68DK7-F1	59.04	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (10): 66, 126, 205, 353, 393, 396, 442, 301, 365, 378

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-3214847	HATs acetylate histones
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization

MSigDB gene sets: 184 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GCM_GSPT1, ONKEN_UVEAL_MELANOMA_UP, GCM_NUMA1, DODD_NASOPHARYNGEAL_CARCINOMA_UP, HOEBEKE_LYMPHOID_STEM_CELL_UP, BILBAN_B_CLL_LPL_DN, GCM_NF2, GNF2_DDX5, GNF2_PTPRC, GNF2_SNRK, GOBP_CHROMATIN_REMODELING, GOCC_H4_HISTONE_ACETYLTRANSFERASE_COMPLEX, GOMF_CHROMATIN_BINDING

GO Biological Process (3): chromatin remodeling (GO:0006338), positive regulation of DNA-templated transcription (GO:0045893), chromatin organization (GO:0006325)

GO Molecular Function (2): protein-macromolecule adaptor activity (GO:0030674), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), nuclear speck (GO:0016607), MSL complex (GO:0072487)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Chromatin organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
chromatin organization	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
cellular component organization	1
protein binding	1
molecular adaptor activity	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nuclear ribonucleoprotein granule	1
H4 histone acetyltransferase complex	1

Protein interactions and networks

STRING

1382 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MSL1	MSL3	Q8N5Y2	980
MSL1	MSL2	Q9HCI7	972
MSL1	TANGO6	Q9C0B7	528
MSL1	DTWD2	Q8NBA8	459
MSL1	JAK1	P23458	451
MSL1	DHX9	Q08211	402
MSL1	DYM	Q7RTS9	394
MSL1	KAT8	Q9H7Z6	390
MSL1	H4C7	Q99525	390
MSL1	KANSL2	Q9H9L4	388
MSL1	H4C16	P02304	379
MSL1	TTYH3	Q9C0H2	349
MSL1	HINT3	Q9NQE9	343
MSL1	GATAD1	Q8WUU5	337
MSL1	KANSL3	Q9P2N6	334

IntAct

50 interactions, top by confidence:

A	B	Type	Score
GMNN	MCIDAS	psi-mi:“MI:0914”(association)	0.770
MSL3	MSL1	psi-mi:“MI:0914”(association)	0.760
WDR5	MEN1	psi-mi:“MI:0914”(association)	0.710
MSL1	MSL2	psi-mi:“MI:0915”(physical association)	0.670
KAT8	MSL1	psi-mi:“MI:0914”(association)	0.640
PBK	TRIM37	psi-mi:“MI:0914”(association)	0.550
MSL1	MSL3B	psi-mi:“MI:0914”(association)	0.530
MSL2	HBB	psi-mi:“MI:0914”(association)	0.530
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
MSL1	TOMM70	psi-mi:“MI:0915”(physical association)	0.400
Kat8	PHF20L1	psi-mi:“MI:0915”(physical association)	0.400
NUPR1	MSL1	psi-mi:“MI:0915”(physical association)	0.370
MSL1	HSPB1	psi-mi:“MI:0915”(physical association)	0.370
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
MSL2	IGHG2	psi-mi:“MI:0914”(association)	0.350
MSL3	TUBA1B	psi-mi:“MI:0914”(association)	0.350
KAT8	HCFC1	psi-mi:“MI:0914”(association)	0.350
KAT8	MSL3B	psi-mi:“MI:0914”(association)	0.350
MSL3	MSL1	psi-mi:“MI:0914”(association)	0.350
SOX2	CBX4	psi-mi:“MI:0914”(association)	0.350
CEP135	MCRIP1	psi-mi:“MI:0914”(association)	0.350
CEP135	WWP2	psi-mi:“MI:0914”(association)	0.350
H2AZ1	SUPT5H	psi-mi:“MI:0914”(association)	0.350

BioGRID (131): MSL1 (Affinity Capture-RNA), MSL1 (Affinity Capture-RNA), MSL1 (Co-localization), MSL1 (Reconstituted Complex), MSL1 (Two-hybrid), MSL1 (Affinity Capture-Western), NUPR1 (Affinity Capture-Western), MSL1 (Reconstituted Complex), TP53BP1 (Two-hybrid), MORF4L1 (Two-hybrid), RAN (Two-hybrid), KPNB1 (Two-hybrid), SNW1 (Two-hybrid), MRGBP (Two-hybrid), PPM1G (Two-hybrid)

ESM2 similar proteins: A0A1L8HBI7, A0A1L8HJK9, A0A1L8HTT5, A6NP61, A8T6P4, C0SPG1, C3VD30, F1N4E5, K7SGN7, O35144, O35253, O70240, O88406, O88566, Q15554, Q1XFL1, Q3ZC82, Q4KLH3, Q5HZN9, Q5JTV8, Q5PQX1, Q5R7A3, Q62315, Q68DK7, Q6P1H6, Q6PDM1, Q6PG95, Q6ZPF3, Q76N89, Q7T3T8, Q7T3T9, Q7T3U0, Q7TNY7, Q7TP65, Q7TSX9, Q80SU3, Q80VM8, Q86XL3, Q8IVF5, Q8K3I4

Diamond homologs: A9JRX0, Q68DK7, Q6PDM1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
MSL1	“form complex”	“MSL acetyltransferase”	binding
MSL1	“down-regulates activity”	H2BC21	monoubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 57 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of WDR5-containing histone-modifying complexes	5	32.4×	8e-05
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	5	17.9×	1e-03
HATs acetylate histones	8	15.5×	1e-05
Formation of the beta-catenin:TCF transactivating complex	5	14.7×	2e-03
G2/M DNA damage checkpoint	5	14.7×	2e-03
Activation of anterior HOX genes in hindbrain development during early embryogenesis	5	11.1×	4e-03
Estrogen-dependent gene expression	5	9.2×	6e-03

GO biological processes:

GO term	Partners	Fold	FDR
chromatin organization	6	11.0×	1e-03
chromatin remodeling	6	8.1×	4e-03
DNA damage response	8	7.9×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

3929 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:40123295:T:C	L228P	1.000
17:40123307:T:C	L232P	1.000
17:40123310:T:A	I233N	1.000
17:40123319:A:C	Q236P	1.000
17:40123322:A:C	Q237P	1.000
17:40123331:T:C	L240P	1.000
17:40123361:T:C	L250P	1.000
17:40126184:T:C	L257P	1.000
17:40126214:G:C	R267P	1.000
17:40132042:T:A	W478R	1.000
17:40132042:T:C	W478R	1.000
17:40132044:G:C	W478C	1.000
17:40132044:G:T	W478C	1.000
17:40133070:G:C	R506P	1.000
17:40133072:C:G	H507D	1.000
17:40133078:A:G	K509E	1.000
17:40133080:A:C	K509N	1.000
17:40133080:A:T	K509N	1.000
17:40133088:T:C	L512P	1.000
17:40133093:G:A	E514K	1.000
17:40133094:A:T	E514V	1.000
17:40133095:G:C	E514D	1.000
17:40133095:G:T	E514D	1.000
17:40133100:G:C	R516T	1.000
17:40133101:A:C	R516S	1.000
17:40133101:A:T	R516S	1.000
17:40133103:G:C	R517T	1.000
17:40133103:G:T	R517M	1.000
17:40133104:G:C	R517S	1.000
17:40133104:G:T	R517S	1.000

dbSNP variants (sampled 300 via entrez): RS1000004266 (17:40132883 T>G), RS1000010481 (17:40121793 G>A,C), RS1000210652 (17:40130830 A>G), RS1000819970 (17:40122264 A>G), RS1000877987 (17:40121575 G>A), RS1001001211 (17:40134153 A>C), RS1001191644 (17:40128137 G>A), RS1001263871 (17:40122285 G>A,C,T), RS1001390872 (17:40127759 T>G), RS1001507452 (17:40126184 T>A), RS1001681073 (17:40134758 T>G), RS1002000491 (17:40128077 G>A), RS1002082167 (17:40123677 G>C,T), RS1002119585 (17:40135584 G>T), RS1002695218 (17:40135518 G>A)

Disease associations

OMIM: gene MIM:614801 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725182 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.79	IC50	1640	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179053: Inhibition of MSL1 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	1.6400	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	9
trichostatin A	decreases expression, affects expression, affects cotreatment	4
Panobinostat	affects expression, increases reaction, decreases expression	2
Lead	affects splicing, decreases expression	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
methylparaben	decreases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
acetochlor	affects methylation, increases abundance	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
apicidin	decreases expression	1
corosolic acid	increases expression	1
scriptaid	decreases expression	1
bazedoxifene	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
(+)-JQ1 compound	affects expression, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Vorinostat	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Antimycin A	increases expression	1
Arsenic	affects methylation	1
Caffeine	affects phosphorylation	1
Doxorubicin	decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697783	Binding	Inhibition of MSL1 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1XP	Abcam HeLa MSL1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.